CPXX selected the ph2 group of AML patients with the most impressive response to its drug- patients with secondary or very high risk AML for its ph3 study. Ph3 of the drug nearing completion with full backing of Leukemia and Lymphoma Society and a market cap for CPXX only a fraction of that of SNSS. I think it has a much better chance for a clinically significant ph3 outcome and big upside potential. I am strongly long CPXX. Take a look at the company website and listen to the last presentation.
you can take it any way you like, this transaction was an exercise of options. He could have kept the 10,000 shares and paid $17400. but chose to sell them for a 459% over their exercise price and pocket $62000 still retaining about 40000 in shares which is what he had before he exercised the options . It was an automatic sale at 8$, when the price spiked the options were excercised and the shares immediately sold. He still has over $298000 in stock which he had when the sale was triggered and hasn't sold. Make of it what you will but he did not lighten his position, I just don't see these sales as a huge negative. Others might disagree but those who are claiming its a strong undeniable indication of the trials success or failure are just plain wrong.
the upside is to small in Suneisis in my opinion. I am betting Panther has the right topo2 drug while it' s early it's based off $400 million of research of Amonafide by various biotech co's. Name of the agent is Numonafide... check it out folks... If upside is only double why wait for the hammer to drop. PBYA has 10X upside.
I find the decision of the DSMB to go ahead and add more patients fulfills their predisposition to only do so if there are signs of any benefits. Given this is a double blind, I guess the decision is based on the data they have unblinded so far? How did they know to add patients because there was a benefit? They would never do this with no data to tell them that there was a benefit. I think it sways a little positive at this point. The sales may be nothing more than tax monies due for exercise of options.
Bjerkholt selling 1/5th of his shares right before data out isn't a little bearish? I mean I don't expect they know what the results are, but they do know the promise zone and a little more info that we do.. I would be skeptical
I have seen you pump CYTR to the low's where it is currently at and bash CYCC (all while it does not fall below the 3's and has recently risen). So, why is that Mr. "Post Opposing Trade Guy"?
Trying to do the math on this one.....any help out there as to why so many sells by insider's at these prices?
Sorry those weren't listed on yahoo when I posted I didn't mean to ignore these sales but they weren't reported when I posted..... but lets look at them too.
Swisher Daniel N JR 5000 shares from Option Exercise at $2.09 per share followed by Automatic Sale at $8 per share. 382% profit So he sold some options which were about to expire but kept 154,073 shares, I wouldn't say this is bearish.
BJERKHOLT ERIC Chief Financial Officer 10000 shares from Option Exercise at $1.74 per share followed by Automatic Sale at $8 per share. 459% profit. So he sold some options which were about to expire still holds 39,994 shares. not overly bearish, he has sold shares before last Feb.
CRAIG ADAM R 2,554 shares Automatic Sale at $8 per share. CMO Holdings 12,723 shares Acquired in Feb at $0.0/ share.
In summary all theses shares were acquired most likely as part of their compensation package and represent a fraction of their holdings as they were all automatic sales at 8.00 these were set to trigger when the price spiked last week. I wouldn't read too much into this take of it what you will All of these officers still have alot of skin in the game so to speak and retain the majority of their holdings. Like I have said It's all going to come down to the results of the Valor trial. I'm holding a position and don't see all the "insider sales" as a reason to run for the hills as all the players still have major positions. The largest volumes were from the funds, and venture captial groups that still each retain over 10% of the company.
Tell us more about your CBMX which is at another 21 month low since you bought it and pumped it for months! Buy sell or hold?
I sharesimilar view of yours on those insider sells. As you stated, they are not out completely and they still hold reasonable amount of shares. To me, this is money vs risk management in case the market perecieve the results in negatively.
It is true that none of the management selling anyshares nor buying any? I would like to see management insiders buying into this at this juncture, that would give good indication and will push the stock PPS above $10.
If you check again, those who sold portions of their holdings have been holding this stock for a long time, some are from 2010. I would have done the same thing especially if i have been waiting for so long, to take some profit off the table and play the remaining, this is common sense.
I have sold ITMN stock $73 recently when the buyout occured, been holding it since 31 all the way to b/o offer, and i have seen couple of insiders selling which was big time misleading the investors and gave an opportunity to short sellers to go even deeper with their positions. At the end, they were all squeezed and yet i believe ITMN has more upside in the coming future (maybe november 23 where FDA approval is expected).
I have a long position in SNSS, and i'm opttimistic that results will be positive, again no one knows for real the status of the data, which i think we will get to witness soon in the coming future.
In statistics, the more data you have the better the analysis can be, and the way i see the increased number of patients is to make sure the data analysis is as accurate as possible.
Exactly, with only 3.6% non-institutional ownership, there is insider trading everyday.
I share your desire to have a drug that is going to change the way AML is treated. I am confident that it is a game changer for this disease.
Sentiment: Strong Buy